Live Breaking News & Updates on Targeted Radionuclide|Page 2

Stay updated with breaking news from Targeted radionuclide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ITM AG: ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021

ITM AG: ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United Kingdom , Fox Chase Cancer Center , United States , City Of , Raj Srirajaskanthan , Simon Singh , Isotopen Technologien , Namrata Vijayvergia , Kostenloser Wertpapierhandel , Steffen Schuster , Desmond James , Udoj Vetter , Sunnybrook Odette Cancer Centre , European Society Of Medical Oncology , King College Hospital , Peter Maccallum Cancer Center , Head Of Marketing Communications , District Court , University Of Toronto , Scientific Program , Deutsche Bank Freiburg , Susanne Karlsson Trophic Communications , Global Perspective , Neuroendocrine Tumors , Evolving Role , Targeted Radionuclide Diagnostics ,

FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.

Press release content from Business Wire. The AP news staff was not involved in its creation.
FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
March 2, 2021 GMT
WEST CHESTER, Pa. (BUSINESS WIRE) Mar 2, 2021
Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE ( 177 Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET). ....

United States , Chris Pak , Clinical Research Organization Newtown , Molecular Targeting Technologies Inc , National Institutes Of Health , Drug Administration , Targeting Technologies , Investigational New Drug , Precision Medicine , Targeted Radionuclide , National Institutes , Cell Thyroid , Clinical Research Organization , Molecular Targeting Technologies , Business Wire , Products And Services , Drug Approvals , Product Approvals , Product Testing , Diagnosis And Treatment , Health Care Industry , New Products And Services , Medical Biotechnology Industry , Clinical Trials , Medical Research , Drug Trials ,